Biomea Fusion, Inc. (BMEA) Current Ratio
- Current ratio · latest quarter: Value 3.47×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.47× | Current assets / current liabilities. $36.43M ÷ $10.48M ≈ 3.47× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 36.43M USD | Assets, Current |
| Current obligations | 10.48M USD | Liabilities, Current |
| Cash and equivalents | 34.82M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 3.31M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $36.43M | $10.48M | $34.82M | (m) | (m) | (m) | $3.31M | (m) | 3.47× |
| 2026-03-31 | $46.32M | $9.29M | $44.69M | (m) | (m) | (m) | $4.61M | (m) | 4.98× |
| 2025-12-31 | $58.05M | $11.10M | $55.81M | (m) | (m) | (m) | $3.23M | (m) | 5.23× |
| 2025-09-30 | $49.44M | $15.56M | $46.64M | (m) | (m) | (m) | $6.40M | (m) | 3.18× |
| 2025-06-30 | $64.66M | $17.57M | $56.22M | (m) | (m) | (m) | $8.38M | (m) | 3.68× |
| 2025-03-31 | $44.69M | $19.82M | $35.86M | (m) | (m) | (m) | $7.71M | (m) | 2.25× |
| 2024-12-31 | $68.33M | $21.67M | $58.28M | (m) | (m) | (m) | $12.93M | (m) | 3.15× |
| 2024-09-30 | $93.60M | $27.57M | $87.95M | (m) | (m) | (m) | $8.99M | (m) | 3.39× |
| 2024-06-30 | $116.29M | $25.16M | $113.29M | (m) | (m) | (m) | $5.83M | (m) | 4.62× |
| 2024-03-31 | $147.57M | $25.25M | $144.92M | (m) | (m) | (m) | $4.71M | (m) | 5.84× |
| 2023-12-31 | $179.18M | $22.86M | $176.87M | (m) | (m) | (m) | $6.85M | (m) | 7.84× |
| 2023-09-30 | $202.50M | $16.21M | $199.09M | (m) | (m) | (m) | $3.19M | (m) | 12.49× |
| 2023-06-30 | $225.94M | $14.36M | $222.91M | (m) | (m) | (m) | $4.15M | (m) | 15.74× |
| 2023-03-31 | $88.93M | $18.77M | $86.30M | (m) | (m) | (m) | $5.33M | (m) | 4.74× |
| 2022-12-31 | $117.82M | $19.10M | $111.90M | (m) | (m) | (m) | $6.83M | (m) | 6.17× |
| 2022-09-30 | $138.86M | $12.59M | $132.31M | (m) | (m) | (m) | $1.59M | (m) | 11.03× |
| 2022-06-30 | $154.14M | $9.36M | $148.48M | (m) | (m) | (m) | $2.41M | (m) | 16.46× |
| 2022-03-31 | $167.02M | $7.96M | $156.22M | (m) | (m) | (m) | $2.52M | (m) | 20.98× |
| 2021-12-31 | $176.56M | $4.64M | $145.74M | (m) | (m) | (m) | $1.33M | (m) | 38.08× |
| 2021-09-30 | $191.10M | $5.64M | $156.97M | (m) | (m) | (m) | $1.25M | (m) | 33.88× |
| 2021-06-30 | $200.52M | $4.94M | $166.04M | (m) | (m) | (m) | $1.35M | (m) | 40.57× |
| 2021-03-31 | $47.52M | $3.92M | $18.89M | (m) | $36.00K | (m) | $969.00K | (m) | 12.13× |
| 2020-12-31 | $62.22M | $1.62M | $61.70M | (m) | (m) | (m) | $727.00K | (m) | 38.43× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |